Janney Capital Management LLC lowered its stake in shares of Johnson & Johnson (NYSE:JNJ) by 2.3% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 304,455 shares of the company’s stock after selling 7,271 shares during the period. Johnson & Johnson makes up 1.7% of Janney Capital Management LLC’s investment portfolio, making the stock its 10th biggest holding. Janney Capital Management LLC’s holdings in Johnson & Johnson were worth $39,582,000 as of its most recent filing with the Securities and Exchange Commission.
Several other hedge funds and other institutional investors also recently made changes to their positions in JNJ. Vanguard Group Inc. raised its holdings in shares of Johnson & Johnson by 1.5% in the 2nd quarter. Vanguard Group Inc. now owns 200,450,985 shares of the company’s stock worth $26,517,661,000 after acquiring an additional 3,023,110 shares during the last quarter. BlackRock Inc. raised its holdings in shares of Johnson & Johnson by 2.6% in the 2nd quarter. BlackRock Inc. now owns 174,073,764 shares of the company’s stock worth $23,028,219,000 after acquiring an additional 4,332,612 shares during the last quarter. Bank of New York Mellon Corp raised its holdings in shares of Johnson & Johnson by 0.4% in the 3rd quarter. Bank of New York Mellon Corp now owns 36,594,054 shares of the company’s stock worth $4,757,593,000 after acquiring an additional 130,437 shares during the last quarter. FMR LLC raised its holdings in shares of Johnson & Johnson by 5.9% in the 2nd quarter. FMR LLC now owns 27,237,648 shares of the company’s stock worth $3,603,268,000 after acquiring an additional 1,509,745 shares during the last quarter. Finally, Capital World Investors raised its holdings in shares of Johnson & Johnson by 4.1% in the 2nd quarter. Capital World Investors now owns 26,510,007 shares of the company’s stock worth $3,507,009,000 after acquiring an additional 1,050,000 shares during the last quarter. Hedge funds and other institutional investors own 67.35% of the company’s stock.
JNJ has been the topic of a number of analyst reports. Vetr upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $150.89 target price on the stock in a report on Thursday, January 11th. Royal Bank of Canada reaffirmed a “buy” rating on shares of Johnson & Johnson in a research report on Tuesday, January 9th. Jefferies Group set a $165.00 price objective on shares of Johnson & Johnson and gave the stock a “buy” rating in a research report on Monday, February 26th. Stifel Nicolaus upped their price objective on shares of Johnson & Johnson from $142.00 to $145.00 and gave the stock a “hold” rating in a research report on Wednesday, January 24th. Finally, Zacks Investment Research downgraded shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a research report on Tuesday, December 12th. Four research analysts have rated the stock with a sell rating, nine have given a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company’s stock. Johnson & Johnson currently has a consensus rating of “Hold” and a consensus target price of $146.26.
In other news, VP Paulus Stoffels sold 155,342 shares of the stock in a transaction that occurred on Thursday, February 15th. The shares were sold at an average price of $129.86, for a total transaction of $20,172,712.12. Following the completion of the transaction, the vice president now directly owns 357,906 shares of the company’s stock, valued at approximately $46,477,673.16. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.19% of the stock is owned by corporate insiders.
Johnson & Johnson (JNJ) opened at $134.35 on Wednesday. Johnson & Johnson has a 52-week low of $120.95 and a 52-week high of $148.32. The firm has a market cap of $360,450.00, a P/E ratio of 24.74, a PEG ratio of 2.19 and a beta of 0.77. The company has a debt-to-equity ratio of 0.51, a quick ratio of 1.12 and a current ratio of 1.41.
Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, January 23rd. The company reported $1.74 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.72 by $0.02. Johnson & Johnson had a net margin of 1.70% and a return on equity of 29.00%. The firm had revenue of $20.20 billion during the quarter, compared to the consensus estimate of $20.08 billion. During the same period in the prior year, the firm earned $1.58 EPS. The company’s revenue was up 11.5% compared to the same quarter last year. sell-side analysts anticipate that Johnson & Johnson will post 8.11 earnings per share for the current fiscal year.
The business also recently announced a quarterly dividend, which was paid on Tuesday, March 13th. Stockholders of record on Tuesday, February 27th were given a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a dividend yield of 2.50%. The ex-dividend date was Monday, February 26th. Johnson & Johnson’s dividend payout ratio is currently 61.88%.
ILLEGAL ACTIVITY WARNING: “Johnson & Johnson (JNJ) Stake Decreased by Janney Capital Management LLC” was first reported by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are reading this article on another site, it was illegally copied and reposted in violation of U.S. and international copyright and trademark legislation. The correct version of this article can be viewed at https://www.thelincolnianonline.com/2018/03/14/johnson-johnson-jnj-stake-decreased-by-janney-capital-management-llc.html.
About Johnson & Johnson
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.